Ribociclib
| Use attributes for filter ! | |
| Formula | C23H30N8O |
|---|---|
| Molar mass | 434. 548 g·mol−1 |
| Other names | LEE 011 |
| Trade name | Kisqali |
| Elimination half-life | 32. 0 (29. 7–54. 7) hrs |
| ATC code | L01XE42 (WHO) |
| Metabolism | CYP3A4 |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951256 |
About Ribociclib
Ribociclib is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.